ICU Medical, Inc. (ICUI)
NASDAQ: ICUI · Real-Time Price · USD
131.38
+1.98 (1.53%)
Mar 25, 2026, 4:00 PM EDT - Market closed
ICU Medical Stock Forecast
Stock Price Forecast
The 4 analysts that cover ICU Medical stock have a consensus rating of "Buy" and an average price target of $182.25, which forecasts a 38.72% increase in the stock price over the next year. The lowest target is $178 and the highest is $191.
Price Target: $182.25 (+38.72%)
Analyst Consensus: Buy
* Price targets were last updated on Feb 20, 2026.
Analyst Ratings
The average analyst rating for ICU Medical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keybanc | Keybanc | Buy Maintains $175 → $180 | Buy | Maintains | $175 → $180 | +37.01% | Feb 20, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $172 → $178 | Buy | Maintains | $172 → $178 | +35.48% | Feb 20, 2026 |
| Keybanc | Keybanc | Buy Maintains $173 → $175 | Buy | Maintains | $173 → $175 | +33.20% | Nov 7, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $153 → $172 | Buy | Maintains | $153 → $172 | +30.92% | Nov 7, 2025 |
| Keybanc | Keybanc | Buy Maintains $191 → $173 | Buy | Maintains | $191 → $173 | +31.68% | Oct 21, 2025 |
Financial Forecast
Revenue This Year
2.22B
from 2.23B
Decreased by -0.50%
Revenue Next Year
2.32B
from 2.22B
Increased by 4.46%
EPS This Year
8.27
from 0.03
Increased by 27,750.39%
EPS Next Year
9.39
from 8.27
Increased by 13.45%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.3B | 2.4B | |||
| Avg | 2.2B | 2.3B | |||
| Low | 2.1B | 2.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3.8% | 9.1% | |||
| Avg | -0.5% | 4.5% | |||
| Low | -5.3% | -1.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 8.59 | 10.13 | |||
| Avg | 8.27 | 9.39 | |||
| Low | 7.89 | 8.62 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 28,812.4% | 22.5% | |||
| Avg | 27,750.4% | 13.5% | |||
| Low | 26,456.0% | 4.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.